Risk factors.
| Allogeneic HSCT . | Type of Secondary Malignancy . | Risk Factor . |
|---|---|---|
| PTLD | EBV+ donor | |
| EBV– patient | ||
| HLA non-identity | ||
| T-cell depletion | ||
| ATG | ||
| Irradiation | ||
| GVHD | ||
| – acute | ||
| – chronic | ||
| Primary disease | ||
| Hematologic disorders | (undetermined) | |
| Solid tumors | Irradiation | |
| Chronic GVHD | ||
| Male gender | ||
| Younger patient age | ||
| T-cell depletion |
| Allogeneic HSCT . | Type of Secondary Malignancy . | Risk Factor . |
|---|---|---|
| PTLD | EBV+ donor | |
| EBV– patient | ||
| HLA non-identity | ||
| T-cell depletion | ||
| ATG | ||
| Irradiation | ||
| GVHD | ||
| – acute | ||
| – chronic | ||
| Primary disease | ||
| Hematologic disorders | (undetermined) | |
| Solid tumors | Irradiation | |
| Chronic GVHD | ||
| Male gender | ||
| Younger patient age | ||
| T-cell depletion |
| Autologous HSCT . | Type of Secondary Malignancy . | Risk Factor . |
|---|---|---|
| Abbreviations: HSCT, hemopoietic stem cell transplantation; PTLD, posttransplant lymphoproliferative disorder; ATG, antithymocyte globulin; GVHD, graft-versus-host disease. | ||
| *In particular, mechlorethamine and chlorambucil have been implicated (C. Metayer et al., unpublished). | ||
| †Available data suggest a higher incidence with the use of peripheral blood stem cells, particularly after mobilization with topoisomerase inhibitors. | ||
| Solid tumors | Irradiation | |
| Virus | ||
| Hematologic disorders | Intensity/duration of pretransplant therapy | |
| Alkylator exposure* | ||
| Conditioning regimen | ||
| Source of stem cells† | ||
| Older patient age | ||
| Autologous HSCT . | Type of Secondary Malignancy . | Risk Factor . |
|---|---|---|
| Abbreviations: HSCT, hemopoietic stem cell transplantation; PTLD, posttransplant lymphoproliferative disorder; ATG, antithymocyte globulin; GVHD, graft-versus-host disease. | ||
| *In particular, mechlorethamine and chlorambucil have been implicated (C. Metayer et al., unpublished). | ||
| †Available data suggest a higher incidence with the use of peripheral blood stem cells, particularly after mobilization with topoisomerase inhibitors. | ||
| Solid tumors | Irradiation | |
| Virus | ||
| Hematologic disorders | Intensity/duration of pretransplant therapy | |
| Alkylator exposure* | ||
| Conditioning regimen | ||
| Source of stem cells† | ||
| Older patient age | ||